Literature DB >> 6368578

Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis.

W F Ebling, S J Szefler, W J Jusko.   

Abstract

A sensitive, selective, and reproducible high-performance liquid chromatographic assay for the simultaneous measurement of cortisol and methylprednisolone using dexamethasone as the internal standard is presented. Samples are extracted with methylene chloride, washed with sodium hydroxide and then water, and chromatographed on a microparticle silica gel column with ultraviolet detection at 254 nm. Sensitivity is greater than 10 ng/ml and the intra-day coefficient of variation is less than 5% for both steroids. The use of porcine liver esterase allows the quantitation of the hemisuccinate ester of methylprednisolone. This assay has been applied in pharmacokinetic studies including investigations of troleandomycin--methylprednisolone interactions. A typical plasma concentration--time profile for methylprednisolone and its ester prodrug is presented for one subject before and after receiving troleandomycin therapy. Although methylprednisolone elimination is reduced in the presence of troleandomycin therapy, there is no effect on the pharmacokinetics of methylprednisolone sodium succinate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368578

Source DB:  PubMed          Journal:  J Chromatogr


  13 in total

1.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

2.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.

Authors:  M A Milad; E A Ludwig; S Anné; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

4.  Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study.

Authors:  Yuen Yi Hon; William J Jusko; Hong-Hao Zhou; Guo-Lin Chen; Dong Guo; Gan Zhou; Vicky E Spratlin; Michael W Jann
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.

Authors:  S J Szefler; W F Ebling; J W Georgitis; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.

Authors:  K H Lew; E A Ludwig; M A Milad; K Donovan; E Middleton; J J Ferry; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

7.  Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.

Authors:  L E Fisher; E A Ludwig; J A Wald; R R Sloan; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

8.  Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit.

Authors:  M M Nieminen; M Hill; C G Irvin
Journal:  Agents Actions       Date:  1991-03

9.  Troleandomycin effects on methylprednisolone and methylprednisone interconversion and disposition in the rabbit.

Authors:  W F Ebling; S A Rich; S J Szefler; W J Jusko
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

10.  Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism.

Authors:  Yuen Yi Hon; William J Jusko; Vicky E Spratlin; Michael W Jann
Journal:  J Clin Pharmacol       Date:  2006-04       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.